Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1. Background, staging and work-up of regional melanoma 2. Evidence for adjuvant and neoadjuvant immunotherapy 3. Adjuvant BRAF/MEK inhibitor  4. Considerations for stage IIB/IIC disease  Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and ot...

1. History of Immunotherapy 2. Modern immune checkpoint inhibitors (ICIs) 3. Unique considerations with ICIs 4. Immune related adverse events and immortal time bias in observational studies   Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO an...

1. BRCA 1/2 genes and relation to malignancy 2. Family history taking and identifying patients for genetic testing 3. Risk reduction strategies for breast and ovarian cancer 4. Systemic therapy considerations in BRCA positive breast cancer  Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourag...

1. Clinical considerations 2. Neoadjuvant and adjuvant regimens 3. Immunotherapy in localized and metastatic disease 4. Later line options in metastatic setting *Erratum- HER-2 Breast cancer <2cm would benefit from an adjuvant regimen (such as trastuzumab and weekly paclitaxel) but typically neoadjuvant is given to 2cm or greater tumors or those that are node positive. Citations As always, cita...

1. Role of adjuvant HER-2 Agents and during of therapy 2. Chemotherapy backbone considerations 3. Pathologic complete response 4. Neoadjuvant systemic therapy and response modified approach Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and...

1. Anti-HER2 agent classes 2. Cleopatra Trial 3. Later line options 4. Leptomeningeal carcinomatosis  Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. DeVita, Vincent T., Jr., Theodore S. Lawrenc...

1. HER-2 Testing Algorithm 2. Trastuzumab Deruxtecan in HER-2 Low MBC 3. 2:1 Randomization, Treatment of Provider Choice 4. Sacutuzumab Govetacan for later line TNBC and HR positive MBC Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and othe...

1.       Endocrine Resistance: Definition and Mechanism 2.       Role of AI with and without CDK4/6 inhibitors 3.       Later line management of metastatic disease 4.       Informative Censoring and the BOLERO-2 trial Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines...

1.       Recurrence Risk Scores 2.       TailorRx, RxPonder, MINDACT Trials Overview 3.       Introduction to CDK 4/6 inhibitors 4.       PALLAS and MONARCH-E Discussion Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations...

1.       Tamoxifen, its development, mechanism and benefits 2.       Aromatase inhibitors and their benefit in post-menopausal state 3.       Nuances on extended endocrine therapy beyond 5 years 4.       SOFT/TEXT, a broad overview of a complex publication Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We...

1.       First, second, and third generation chemotherapy regimens 2.       Considerations for anthracyclines  3.       Considerations for taxanes 4.       Adjuvant bisphosphonates Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other org...

1.       History of surgery and radiation for breast cancer 2.       Indication and goal of adjuvant systemic therapy (incl cell-kill hypothesis) 3.       Overview of breast cancer subtypes 4.       Strategies and guidelines for surveillance Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encoura...

1.       Overview of disease site 2.       Management of localized disease 3.       Surveillance 4.       Metastatic Disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & P...

1.       RAPIDO Trial  2.       PRODIGE-23 Trial  3.       OPRA Trial  4.       Evidence for non-operative potential in MSI-H tumors with immune checkpoint inhibition Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and R...

1.       Anatomy, definitions, and unique considerations vs colon cancer 2.       Surgical modalities and patterns of failure 3.       Perioperative radiation and chemoradiation 4.       Evidence to support adjuvant systemic therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., The...

1.       Overview of intrahepatic, perihilar, distal cholangiocarcinoma 2.       Overview of gall bladder adenocarcinoma 3.       Adjuvant chemoradiation and chemotherapy considerations 4.       Per-protocol, intention to treat analysis, historical controls Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeV...

1.       Overview of nomenclature, etiology and presentation 2.       Management of symptoms and prognosis 3.       Systemic therapy in the first line 4.       Second line and biomarker driven management Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven...

1.       Differential for pancreatic lesion, staging of adenocarcinoma 2.       Surgical considerations, post-surgical complications 3.       Historical adjuvant evidence 4.       An argument for neoadjuvant systemic therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S....

1.      Natural history of disease, presentation, and diagnosis 2.      Principles of management 3.      Landmark clinical trials 4.      Targeted therapy options as of 2022 Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman...

1.      Principles of management 2.      Key chemotherapy tegimens 3.      Immunotherapy/HER-2 Directed Approach 4.      Alpha spending, hierarchical statistical design 5.      Later line approach and bottom lines to approach Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S...

1.       Anatomy of the Upper GI Tract 2.       Diagnosis, Staging Work-up 3.       Neoadjuvant Chemoradiation for Esophageal/EGJ 4.       Perioperative and Adjuvant Gastric/EGJ 5.       Checkmate 577 discussion Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, an...

IDEA Trial Discussion 1.      Background/Methods 2.      Non-inferiority Trial Design Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Phil...

1.      Clinical Presentation, Pathology Evaluation 2.      Chemotherapy Regimens in Adjuvant Setting 3.      Approach to Stage 3 4.      Approach to Stage 2 Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg&...

1.      Background on molecular targeted agents 2.      VEGF-inhibitors 3.      EGFR inhibition 4.      Left vs Right sided colon cancer 5.      MSI-H/dMMR status  Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rose...

Overview of our podcast and goal.